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Comment Jonathan Skinner
There are few analyses of pharmaceutical drug utilization in the general el-
derly population, and most of those are cross-sectional (e.g., Safran et al.
[2005], although see Centers for Medicare and Medicaid Services [CMS]
n.d.). Thus, Bhattacharya, Garber, and MaCurdy should get special credit
for tackling an extremely diﬃcult problem, which is tracking prescription
drug use among the elderly and disabled population between 1992 and
2001. The Medicare Current Beneﬁciary Survey (MCBS) can be extremely
tricky to use as a longitudinal data set, and the fact that their estimates look
reasonable and tell a compelling story is all the more remarkable. For this
alone, the authors deserve applause. Understanding pharmaceutical cost
growth is a particularly important topic, given the future potential of even
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D plan takes eﬀect.
In these comments, I make two general points. First, the paper raises a
number of fascinating issues surrounding the substitution eﬀects between
prescription drug use and more conventional (Part A and B) health care
expenditures. Is it possible to get traction on this important question using
these MCBS data—for example, are regions where pharmaceutical expen-
ditures are rising the most rapidly also the ones experiencing the most
modest growth in conventional health expenditures? Or are regions where
pharmaceutical utilization is rising most rapidly (for example, in the use of
cholesterol-lowering statin drugs) also the ones where speciﬁc illnesses are
falling the most rapidly (e.g., cardiac disease)? These are all questions that
could be addressed using these data, and I look forward to seeing more.
And second, the paper is motivated by the ongoing debate regarding the
future progression of disability. In the view of Manton and his colleagues,
we can look forward to a steady downward trend in disability among 
the elderly population (Manton, Corder, and Stallard 1997). By contrast,
Bhattacharya and his colleagues suggest that rising patterns of obesity and
mental illness currently in the middle-aged population could lead to in-
creasing disability rates in the future, with presumably adverse conse-
quences for the Medicare budget (Lakdawalla et al. 2003). Fortuitously,
the data presented here by the researchers shed light on this debate because
they have carefully estimated levels and growth for both disability rates and
expenditures on pharmaceuticals conditional on disability. In the follow-
ing, I consider whether we need to know the resolution of this debate be-
fore we can reasonably predict or forecast future pharmaceutical (and
overall) health care costs.
Bhattacharya, Garber, and MaCurdy consider four populations en-
rolled in the Medicare program: those under age sixty-ﬁve on Social Secu-
rity Disability Insurance, elderly people without any deﬁcits in their Ac-
tivities of Daily Living (ADL   zero), moderately disabled (one to two
ADLs), and more severely disabled elderly people (three or more ADLs).
Figure 8.1 in their paper shows remarkable similarities in the growth rates
from 1992 to 2001 of pharmaceutical expenditures within each of the four
groups. By my crude approximations, annual nominal expenditure growth
for each group appears to lie within a remarkably narrow band of 11 to 12
percent.1
We also know from the authors’ table 8.1, both levels and changes in these
categories during the period 1992 to 2000. (Assume the 2000 disability mea-
sures are matched to the 2001 expenditures.) My ﬁgure 8C.1 uses their data
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1. After adjusting by the gross domestic product (GDP) deﬂator, real expenditure growth









































































































































































































.to show the breakdown of the population served by the Medicare program,
including the under-sixty-ﬁve population covered under Disability Insur-
ance. In 1992, 10 percent of the total covered Medicare population was dis-
abled and under age sixty-ﬁve, 18 percent were over sixty-ﬁve and experi-
enced one or two ADLs, and 9 percent were elderly and experienced three
or more. The remainder, 63 percent were over sixty-ﬁve but without any dis-
ability. By 2000, the percent disabled had climbed to 13 percent, but the
fraction of elderly people with ADLs had fallen (ﬁgure 8C.l). How much of
an impact did the slight decline in disability have on per capita pharmaceu-
tical expenditures? The short answer is: barely detectable.
This point can be made more forcefully by taking an extreme counter-
factual case. Assume a magic drug that cuts disability rates in the U.S. pop-
ulation by more than 50 percent. In this happy counterfactual world, dis-
ability rates have plummeted to just 5 percent (under sixty-ﬁve), 5 percent
(three or more ADLs) and 10 percent (one to two ADLs) in 2000 (see ﬁg-
ure 8C.1). In contrast to the true rate of 65 percent of the enrolled Medi-
care population with no ADLs, this counterfactual case assumes that 80
percent of the population has no disabilities.
Had this occurred, what would have happened to growth rates in phar-
maceutical expenditures? Still not much. Rather than annual growth rates
of 11.5 percent, there would have been growth rates of 10.4 percent. Both
growth rates are likely to be unsustainable, although at a rate of 11.5 per-
cent, the day of reckoning will arrive somewhat earlier, a point made more
generally for Medicare expenditure projections in Lee and Skinner (1999).
This result contrasts with the work by Bhattacharya et al. (2004), who sug-
gest that Medicare expenditures will actually decline in the short term be-
cause of improvements in disability. However, their result is easily under-
stood given that they assume future disability-constant growth rates in
Medicare expenditures to be equal to the inﬂation rate. In their projection,
real Medicare expenditures (adjusted for inﬂation) will clearly decline as
the population becomes healthier, at least for the next several decades.
But as long as overall medical expenditures grow substantially more rap-
idly than inﬂation—as has been the case for the last half-century—the
importance of changes in disability for spending projections will remain
second-order. This is not to say that disability rates aren’t of ﬁrst-order im-
portance to the health and well-being of the American population. Indeed,
were disability rates to attain the desirable levels posited in the counterfac-
tual, an 11.5 percent growth rate in pharmaceutical expenditures would be
well worth it.
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